Amarin (AMRN) to Present Data from Pivotal ANCHOR Phase 3 at ADA's 72nd Scientific Sessions
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin Corporation plc (Nasdaq: AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that data from the AMR101 pivotal Phase 3 ANCHOR study will be presented in a poster at the American Diabetes Association's (ADA) 72nd Scientific Sessions at the Pennsylvania Convention Center in Philadelphia, Pennsylvania on June 9, 2012.
The poster, titled "Effects of AMR101 on Lipid and Inflammatory Parameters in Patients with Diabetes Mellitus-2 (Type 2) and Residual Elevated Triglycerides (200-500 mg/dL) on Statin Therapy at LDL-C Goal: The ANCHOR Study," will present an analysis of the effect on lipid and inflammatory parameters in patients with diabetes from Amarin's Phase 3 ANCHOR study. The ANCHOR study, a multicenter, placebo-controlled, randomized, double-blind, 12-week study, investigated AMR101 as a treatment for patients with high triglycerides (≥200 and <500 mg/dL) who were also on statin therapy for elevated low-density lipoprotein cholesterol. Of 702 total patients, 514 (73%) had diabetes mellitus-2.
The poster, titled "Effects of AMR101 on Lipid and Inflammatory Parameters in Patients with Diabetes Mellitus-2 (Type 2) and Residual Elevated Triglycerides (200-500 mg/dL) on Statin Therapy at LDL-C Goal: The ANCHOR Study," will present an analysis of the effect on lipid and inflammatory parameters in patients with diabetes from Amarin's Phase 3 ANCHOR study. The ANCHOR study, a multicenter, placebo-controlled, randomized, double-blind, 12-week study, investigated AMR101 as a treatment for patients with high triglycerides (≥200 and <500 mg/dL) who were also on statin therapy for elevated low-density lipoprotein cholesterol. Of 702 total patients, 514 (73%) had diabetes mellitus-2.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin to present REDUCE-IT analyses at ESC Congress 2026
- Mistral and Humain announce AI collaboration worth hundreds of millions
- FingerMotion CEO outlines AI computing expansion in North America
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
